Organ-Specific Efficacy of Postischemic Empagliflozin in Acute Stroke and Myocardial Infarction Using Preclinical Models.
Authors:
Journal: Journal of the American Heart Association
Publication Type: Journal Article
Date: 2026
DOI: 10.1161/JAHA.125.047087
ID: 42216277
Abstract
Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, has demonstrated cardioprotective and neuroprotective effects in preclinical myocardial infarction (MI) and ischemic stroke settings by reducing acute myocardial and cerebral infarction sizes. However, the optimal administration for acute protection remains unclear. Particularly, empagliflozin effects when administered after ischemia onset but before reperfusion have not been systematically evaluated for acute MI and stroke models.
Chemical List
- empagliflozin|||Benzhydryl Compounds|||Glucosides|||Sodium-Glucose Transporter 2 Inhibitors|||Neuroprotective Agents
Reference List
- Martin SS, Aday AW, Allen NB, Almarzooq ZI, Anderson CA, Arora P, Avery CL, Baker‐Smith CM, Bansal N, Beaton AZ. 2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2025;151:e41–e660. doi: 10.1161/CIR.0000000000001303|||Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413–1424. doi: 10.1056/NEJMoa2022190|||Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA‐REG OUTCOME® trial. Eur Heart J. 2016;37:1526–1534. doi: 10.1093/eurheartj/ehv728|||Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128. doi: 10.1056/NEJMoa1504720|||Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J, Mattheus M, Zwiener I, Amir O, Bahit MC. Empagliflozin after acute myocardial infarction. N Engl J Med. 2024;390:1455–1466. doi: 10.1056/NEJMoa2314051|||von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, Alber H, Berger R, Lichtenauer M, Saely CH. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022;43:4421–4432. doi: 10.1093/eurheartj/ehac494|||Dai W, Alavi R, Li J, Carreno J, Pahlevan NM, Kloner RA. Empagliflozin demonstrates neuroprotective and cardioprotective effects by reducing ischemia/reperfusion damage in rat models of ischemic stroke and myocardial infarction. Sci Rep. 2025;15:8986. doi: 10.1038/s41598-025-93483-7|||Nikolaou PE, Konijnenberg LS, Kostopoulos IV, Miliotis M, Mylonas N, Georgoulis A, Pavlidis G, Kuster CT, van Reijmersdal VP, Luiken TT. Empagliflozin in acute myocardial infarction reduces no‐reflow and preserves cardiac function by preventing endothelial damage. Basic Transl Sci. 2025;10:43–61. doi: 10.1016/j.jacbts.2024.08.003|||Andreadou I, Efentakis P, Balafas E, Togliatto G, Davos CH, Varela A, Dimitriou CA, Nikolaou P‐E, Maratou E, Lambadiari V. Empagliflozin limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects. Front Physiol. 2017;8:1077. doi: 10.3389/fphys.2017.01077|||Lu Q, Liu J, Li X, Sun X, Zhang J, Ren D, Tong N, Li J. Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway. Mol Cell Endocrinol. 2020;501:110642. doi: 10.1016/j.mce.2019.110642|||Yang W, Kim J‐M, Chung M, Ha J, Kang D‐W, Lee E‐J, Jeong H‐Y, Jung K‐H, Sung H, Paeng JC. Sodium‐glucose cotransporter 2 inhibitor improves neurological outcomes in diabetic patients with acute ischemic stroke. J Stroke. 2024;26:342–346. doi: 10.5853/jos.2023.04056|||Takashima M, Nakamura K, Kiyohara T, Wakisaka Y, Hidaka M, Takaki H, Yamanaka K, Shibahara T, Wakisaka M, Ago T. Low‐dose sodium‐glucose cotransporter 2 inhibitor ameliorates ischemic brain injury in mice through pericyte protection without glucose‐lowering effects. Commun Biol. 2022;5:653. doi: 10.1038/s42003-022-03605-4|||Vercalsteren E, Karampatsi D, Buizza C, Nyström T, Klein T, Paul G, Patrone C, Darsalia V. The SGLT2 inhibitor empagliflozin promotes post‐stroke functional recovery in diabetic mice. Cardiovasc Diabetol. 2024;23:88. doi: 10.1186/s12933-024-02174-6|||Hierro‐Bujalance C, Infante‐Garcia C, Del Marco A, Herrera M, Carranza‐Naval MJ, Suarez J, Alves‐Martinez P, Lubian‐Lopez S, Garcia‐Alloza M. Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes. Alzheimer's Res Ther. 2020;12:1–13. doi: 10.1186/s13195-020-00607-4|||Avgerinos KI, Mullins RJ, Vreones M, Mustapic M, Chen Q, Melvin D, Kapogiannis D, Egan JM. Empagliflozin induced ketosis, upregulated IGF‐1/insulin receptors and the canonical insulin signaling pathway in neurons, and decreased the excitatory neurotransmitter glutamate in the brain of non‐diabetics. Cells. 2022;11:3372. doi: 10.3390/cells11213372|||Connelly KA, Zhang Y, Desjardins J‐F, Nghiem L, Visram A, Batchu SN, Yerra VG, Kabir G, Thai K, Advani A. Load‐independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. Cardiovasc Diabetol. 2020;19:1–11. doi: 10.1186/s12933-020-0994-y|||Kim S, Jo CH, Kim G‐H. Effects of empagliflozin on nondiabetic salt‐sensitive hypertension in uninephrectomized rats. Hypertens Res. 2019;42:1905–1915. doi: 10.1038/s41440-019-0326-3|||Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20:84–91. doi: 10.1161/01.STR.20.1.84|||Amini N, Sarkaki A, Dianat M, Mard SA, Ahangarpour A, Badavi M. Naringin and trimetazidine improve baroreflex sensitivity and nucleus tractus solitarius electrical activity in renal ischemia‐reperfusion injury. Arq Bras Cardiol. 2021;117:290–297. doi: 10.36660/abc.20200121|||Sysoev YI, Prikhodko VA, Kan AV, Titovich IA, Karev VE, Okovityi SV. Changes in brain electrical activity after transient middle cerebral artery occlusion in rats. Neurol Int. 2022;14:547–560. doi: 10.3390/neurolint14030044|||Liu S, Zhen G, Meloni BP, Campbell K, Winn HR. Rodent stroke model guidelines for preclinical stroke trials. J Exp Stroke Transl Med. 2009;2:2. doi: 10.6030/1939-067x-2.2.2|||Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, Bartkowski HM. Evaluation of 2, 3, 5‐triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke. 1986;17:1304–1308. doi: 10.1161/01.STR.17.6.1304|||Reglodi, D. , Tamás, A. , Somogyvári‐Vigh, A. , Szántó, Z. , Kertes, E. , Lénárd, L. , Arimura, A. , Lengvári, I. (2002). Effects of pretreatment with PACAP on the infarct size and functional outcome in rat permanent focal cerebral ischemia. Peptides, 23(12), 2227–2234. 10.1016/s0196-9781(02)00262-0|||Paxinos G, Watson C. The rat brain in stereotaxic coordinates: hard cover edition. Elsevier; 2006.|||Lindsey ML, Bolli R, Canty JM, Du XJ, Frangogiannis NG, Frantz S, Gourdie RG, Holmes JW, Jones SP, Kloner RA, et al. Guidelines for experimental models of myocardial ischemia and infarction. Am J Physiol Heart Circ Physiol. 2018;314:H812–H838. doi: 10.1152/ajpheart.00335.2017|||Alavi R, Li J, Lin J, Dai W, Pahlevan N, Gharib M, Kloner R. Deep learning segmentation for automated measurement of infarct size in preclinical myocardial infarction models. Circulation. 2025;152(Suppl_3):A4369860. doi: 10.1161/circ.152.suppl_3.4369860|||Abdel‐Latif RG, Rifaai RA, Amin EF. Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia/reperfusion injury through HIF‐1α/VEGF signaling pathway. Arch Pharm Res. 2020;43:514–525. doi: 10.1007/s12272-020-01237-y|||Amin EF, Rifaai RA, Abdel‐latif RG. Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative–inflammatory–apoptotic pathway. Fundam Clin Pharmacol. 2020;34:548–558. doi: 10.1111/fcp.12548|||Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa T, Kusaka H, Kim‐Mitsuyama S. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13:1–15. doi: 10.1186/s12933-014-0148-1|||Millar P, Pathak N, Parthsarathy V, Bjourson AJ, O'Kane M, Pathak V, Moffett RC, Flatt PR, Gault VA. Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice. J Endocrinol. 2017;234:255–267. doi: 10.1530/joe-17-0263|||Dai W, Alavi R, Li J, Carreno J, Pahlevan N, Arakaki X, Kloner R. Post‐ischemic administration of empagliflozin reduces cerebral infarction but not edema in a rat ischemic stroke model. Circulation. 2025;152(Suppl_3):A4364551. doi: 10.1161/circ.152.suppl_3.4364551|||Dai W, Carreno J, Pahlevan N, Alavi R, Kloner R. Empagliflozin dramatically reduced stroke size and cerebral edema in a rat model. Circulation. 2024;150(Suppl_1):A4141798. doi: 10.1161/circ.150.suppl_1.4141798|||Gotoh O, Asano T, Koide T, Takakura K. Ischemic brain edema following occlusion of the middle cerebral artery in the rat. I: the time courses of the brain water, sodium and potassium contents and blood‐brain barrier permeability to 125I‐albumin. Stroke. 1985;16:101–109. doi: 10.1161/01.STR.16.1.101|||Neumann‐Haefelin T, Kastrup A, De Crespigny A, Yenari M, Ringer T, Sun G, Moseley M. Serial MRI after transient focal cerebral ischemia in rats: dynamics of tissue injury, blood‐brain barrier damage, and edema formation. Stroke. 2000;31:1965–1973. doi: 10.1161/01.str.31.8.1965|||Dzialowski I, Klotz E, Goericke S, Doerfler A, Forsting M, von Kummer R. Ischemic brain tissue water content: CT monitoring during middle cerebral artery occlusion and reperfusion in rats. Radiology. 2007;243:720–726. doi: 10.1148/radiol.2432060137|||Dai W, Carreno J, Pahlevan N, Alavi R, Chavez J, Kloner R. Empagliflozin reduces both infarct size and no‐reflow in a rat experimental myocardial ischemia/reperfusion model. Circulation. 2024;150(Suppl_1):A4141695. doi: 10.1161/circ.150.suppl_1.4141695|||d'Avila JC, Carlos AS, Vieira RL, Vergueiro C, Lima AT, Silva IS, de Figueiredo VC, Chateaubriand PHP, Moreno AM, de Castro Faria Neto HC. Beneficial effects of empagliflozin and liraglutide on the cerebral microcirculation of diabetic rats. Microcirculation. 2023;30:e12825. doi: 10.1111/micc.12825|||Hierro‐Bujalance C, Garcia‐Alloza M. Empagliflozin reduces brain pathology in Alzheimer's disease and type 2 diabetes. Neural Regen Res. 2024;19:1189–1190. doi: 10.4103/1673-5374.385865|||Hershenson R, Nardi‐Agmon I, Leshem‐Lev D, Kornowski R, Eisen A. The effect of empagliflozin on circulating endothelial progenitor cells in patients with diabetes and stable coronary artery disease. Cardiovasc Diabetol. 2024;23:386. doi: 10.1186/s12933-024-02466-x|||Pawlos A, Broncel M, Woźniak E, Gorzelak‐Pabiś P. Neuroprotective effect of SGLT2 inhibitors. Molecules. 2021;26:7213. doi: 10.3390/molecules26237213|||Bonnin P, Kubis N, Charriaut‐Marlangue C. Collateral supply in preclinical cerebral stroke models. Transl Stroke Res. 2022;13:512–527. doi: 10.1007/s12975-021-00969-3|||Li L, Tovmasyan A, Sheng H, Xu B, Sampaio RS, Reboucas JS, Warner DS, Batinic‐Haberle I, Spasojevic I. Fe porphyrin‐based SOD mimic and redox‐active compound,(OH) FeTnHex‐2‐PyP4+, in a rodent ischemic stroke (MCAO) model: efficacy and pharmacokinetics as compared to its Mn analogue,(H2O) MnTnHex‐2‐PyP5+. Antioxidants. 2020;9:467. doi: 10.3390/antiox9060467|||Hochrainer K, Hansen A, Garcia‐Bonilla L. Keep your guard up: blood–brain barrier protection by empagliflozin after acute ischaemic stroke. Oxford University Press UK; 2025:694–696.|||Liu G, Qiu Y, You N, Yu M, Chen W, Sun T, Qin Z, Han M, Xue Z, Liang X. Pre‐ischaemic empagliflozin treatment attenuates blood–brain barrier disruption via β‐catenin mediated protection of cerebral endothelial cells. Cardiovasc Res. 2025;121:788–802. doi: 10.1093/cvr/cvaf026|||Coyle P, Heistad DD. Blood flow through cerebral collateral vessels in hypertensive and normotensive rats. Hypertension. 1986;8(6_pt_2):II67. doi: 10.1161/01.hyp.8.6_pt_2.ii67|||Cuccione E, Versace A, Cho T‐H, Carone D, Berner L‐P, Ong E, Rousseau D, Cai R, Monza L, Ferrarese C. Multi‐site laser Doppler flowmetry for assessing collateral flow in experimental ischemic stroke: validation of outcome prediction with acute MRI. J Cereb Blood Flow Metab. 2017;37:2159–2170. doi: 10.1177/0271678X16661567|||Zhang H, Faber JE. De‐novo collateral formation following acute myocardial infarction: dependence on CCR2+ bone marrow cells. J Mol Cell Cardiol. 2015;87:4–16. doi: 10.1016/j.yjmcc.2015.07.020|||Hale SL, Kloner RA. Effect of early coronary artery reperfusion on infarct development in a model of low collateral flow. Cardiovasc Res. 1987;21:668–673. doi: 10.1093/cvr/21.9.668|||Ma J, Ma Y, Shuaib A, Winship IR. Impaired collateral flow in pial arterioles of aged rats during ischemic stroke. Transl Stroke Res. 2020;11:243–253. doi: 10.1007/s12975-019-00710-1|||Wang J, Lin X, Mu Z, Shen F, Zhang L, Xie Q, Tang Y, Wang Y, Zhang Z, Yang G‐Y. Rapamycin increases collateral circulation in rodent brain after focal ischemia as detected by multiple modality dynamic imaging. Theranostics. 2019;9:4923–4934. doi: 10.7150/thno.32676|||Uriuda Y, Wang Q‐D, Li X‐S, Sjöquist P‐O, Nordlander R, Rydén L. Coronary venous drug infusion in the ischaemic‐reperfused isolated rat heart. Cardiovasc Res. 1996;31:82–92. doi: 10.1016/S0008-6363(95)00162-X|||Opitz CF, Mitchell GF, Pfeffer MA, Pfeffer JM. Arrhythmias and death after coronary artery occlusion in the rat: continuous telemetric ECG monitoring in conscious, untethered rats. Circulation. 1995;92:253–261. doi: 10.1161/01.cir.92.2.253|||Dai W, Amoedo ND, Perry J, Le Grand B, Boucard A, Carreno J, Zhao L, Brown DA, Rossignol R, Kloner RA. Effects of OP2113 on myocardial infarct size and no reflow in a rat myocardial ischemia/reperfusion model. Cardiovasc Drugs Ther. 2022;1–11:217–227. doi: 10.1007/s10557-020-07113-7|||Popp A, Jaenisch N, Witte OW, Frahm C. Identification of ischemic regions in a rat model of stroke. PLoS One. 2009;4:e4764. doi: 10.1371/journal.pone.0004764|||Carmichael ST. Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx. 2005;2:396–409. doi: 10.1602/neurorx.2.3.396|||Sokolowski JD, Soldozy S, Sharifi KA, Norat P, Kearns KN, Liu L, Williams AM, Yağmurlu K, Mastorakos P, Miller GW. Preclinical models of middle cerebral artery occlusion: new imaging approaches to a classic technique. Front Neurol. 2023;14:1170675. doi: 10.3389/fneur.2023.1170675|||Mroueh A, Algara‐Suarez P, Fakih W, Gong D‐S, Matsushita K, Park S‐H, Amissi S, Auger C, Kauffenstein G, Meyer N. SGLT2 expression in human vasculature and heart correlates with low‐grade inflammation and causes eNOS‐NO/ROS imbalance. Cardiovasc Res. 2025;121:643–657. doi: 10.1093/cvr/cvae257|||Marfella R, Scisciola L, D'Onofrio N, Maiello C, Trotta MC, Sardu C, Panarese I, Ferraraccio F, Capuano A, Barbieri M. Sodium‐glucose cotransporter‐2 (SGLT2) expression in diabetic and non‐diabetic failing human cardiomyocytes. Pharmacol Res. 2022;184:106448. doi: 10.1016/j.phrs.2022.106448|||Cechetto DF, Wilson JX, Smith KE, Wolski D, Silver MD, Hachinski VC. Autonomic and myocardial changes in middle cerebral artery occlusion: stroke models in the rat. Brain Res. 1989;502:296–305. doi: 10.1016/0006-8993(89)90625-2|||Cheung RT, Hachinski VC, Cechetto DF. Cardiovascular response to stress after middle cerebral artery occlusion in rats. Brain Res. 1997;747:181–188. doi: 10.1016/S0006-8993(96)01137-7|||Schoemaker R, Urquhart J, Debets J, Struyker Boudier H, Smits J. Acute hemodynamic effects of coronary artery ligation in conscious rats. Basic Res Cardiol. 1990;85:9–20. doi: 10.1007/BF01907010|||Li J, Alavi R, Dai W, Carreno J, Pahlevan N, Arakaki X, Gharib M, Kloner R. Abstract TP371: effects of empagliflozin on ischemic stroke in a rat model: time‐frequency electroencephalogram features and cerebral infarction size. Stroke. 2025;56(Suppl_1):ATP371. doi: 10.1161/str.56.suppl_1.TP371|||Sorop O, van de Wouw J, Chandler S, Ohanyan V, Tune JD, Chilian WM, Merkus D, Bender SB, Duncker DJ. Experimental animal models of coronary microvascular dysfunction. Cardiovasc Res. 2020;116:756–770. doi: 10.1093/cvr/cvaa002|||Seiler C, Stoller M, Pitt B, Meier P. The human coronary collateral circulation: development and clinical importance. Eur Heart J. 2013;34:2674–2682. doi: 10.1093/eurheartj/eht195|||Liu X, Dong H, Huang B, Miao H, Xu Z, Yuan Y, Qiu F, Chen J, Zhang H, Liu Z. Native coronary collateral microcirculation reserve in rat hearts. J Am Heart Assoc. 2019;8:e011220. doi: 10.1161/JAHA.118.011220|||Stoller M, Seiler C. Salient features of the coronary collateral circulation and its clinical relevance. Swiss Med Wkly. 2015;145:w14154. doi: 10.4414/smw.2015.14154|||Seefeldt JM, Lassen TR, Hjortbak MV, Jespersen NR, Kvist F, Hansen J, Bøtker HE. Cardioprotective effects of empagliflozin after ischemia and reperfusion in rats. Sci Rep. 2021;11:9544. doi: 10.1038/s41598-021-89149-9|||Lim VG, Bell RM, Arjun S, Kolatsi‐Joannou M, Long DA, Yellon DM. SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart. JACC: Basic Transl Sci. 2019;4:15–26. doi: 10.1016/j.jacbts.2018.10.002|||Daud E, Ertracht O, Bandel N, Moady G, Shehadeh M, Reuveni T, Atar S. The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non‐diabetic rats. Cardiovasc Diabetol. 2021;20:132. doi: 10.1186/s12933-021-01322-6|||Yurista SR, Silljé HH, Oberdorf‐Maass SU, Schouten EM, Pavez Giani MG, Hillebrands JL, van Goor H, van Veldhuisen DJ, de Boer RA, Westenbrink BD. Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail. 2019;21:862–873. doi: 10.1002/ejhf.1473|||Jespersen NR, Lassen T, Hjortbak MV, Stottrup N, Botker H. Sodium glucose transporter 2 (SGLT2) inhibition does not protect the myocardium from acute ischemic reperfusion injury but modulates post‐ischemic mitochondrial function. Cardiovasc Pharmacol Open Access. 2017;6:2–4. doi: 10.4172/2329-6607.1000210|||Prendes MM, García J, Fernández M, Pérez M, Perazzo J, Savino E, Varela A. Effects of 5‐hydroxydecanoate and ischemic preconditioning on the ischemic‐reperfused heart of fed and fasted rats. J Physiol Biochem. 2005;61:447–456. doi: 10.1007/BF03168451|||Chen S, Wang Q, Bakker D, Hu X, Zhang L, van der Made I, Tebbens AM, Kovácsházi C, Giricz Z, Brenner GB. Empagliflozin prevents heart failure through inhibition of the NHE1‐NO pathway, independent of SGLT2. Basic Res Cardiol. 2024;119:751–772. doi: 10.1007/s00395-024-01067-9|||Alavi R, Dai W, Li J, Carreno J, Pahlevan N, Arakaki X, Gharib M, Kloner R. Alterations in heart rate variability after ischemic stroke in rats: heart‐brain connectivity. Stroke. 2025;56(Suppl_1):ATP381. doi: 10.1161/str.56.suppl_1.TP381|||Alavi R, Li J, Dai W, Carreno J, Arakaki X, Pahlevan N, Gharib M, Kloner R. New insights from time‐frequency analysis of electroencephalogram throughout ischemic stroke in rats. Stroke. 2025;56(Suppl_1):AWP382. doi: 10.1161/str.56.suppl_1.WP382|||Niroumandi S, Wei H, Amlani F, Gorji H, Alavi R, Chirinos JA, Pahlevan NM. Time‐frequency machine learning transfer function for central pressure waveforms. Eur Heart J Open. 2025;5:oeaf082. doi: 10.1093/ehjopen/oeaf082|||Li J, Alavi R, Dai W, Carreno J, Kloner R, Pahlevan N. Evidence of cerebral vascular stunning following ischemic stroke revealed by myogenic oscillatory activity in rats. Circulation. 2025;152(Suppl_3):A4368147. doi: 10.1161/circ.152.suppl_3.4368147|||Li J, Alavi R, Dai W, Matthews RV, Kloner RA, Pahlevan NM. Assessment of myocardial injury size metrics using carotid pressure waveform: proof‐of‐concept in coronary occlusion/reperfusion rat model. FASEB J. 2025;39:e71029. doi: 10.1096/fj.202502111R|||Alavi R, Dai W, Matthews RV, Kloner RA, Pahlevan NM. Instantaneous detection of acute myocardial infarction and ischaemia from a single carotid pressure waveform in rats. Eur Heart J Open. 2023;3:oead099. doi: 10.1093/ehjopen/oead099